Acute disseminated encephalomyelitis

The frequency of CNS neuroinflammatory events reported in the literature after both SARS-CoV-2 infection and COVID-19 vaccination is still largely unknown. While these conditions can occur spontaneously, they have also been reported following vaccinations, including those for influenza, hepatitis B, human papillomavirus, and COVID-19. Viruses and their vaccines may unmask CNS neuroinflammatory conditions. 

A 47-year-old man with a history of psoriasis and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection presented with 3 months of subacute lower extremity weakness, erectile dysfunction, and gait instability with falls. His symptoms started 2 weeks after receiving the second of his 2-shot primary mRNA vaccine series for coronavirus disease 2019 (COVID-19) vaccination, which he received 3 months after a mild case of COVID-19. He had no other relevant medical or family history and no recent travel. After evaluation by a urologist, he was prescribed a course of cefdinir for presumed prostatitis. His weakness and gait dysfunction worsened over the ensuing 3 months despite this treatment and prompted his presentation to our hospital.

The multifocal, perivascular enhancing lesions in the brain and spinal cord were consistent with relapsing steroid-responsive encephalomyelitis after SARS-CoV-2 infection and subsequent COVID-19 vaccination. This is the first reported case of relapsing steroid-responsive encephalomyelitis after COVID-19 vaccination. 

The patient was diagnosed with immune-mediated encephalomyelitis. The primary cause was felt to be immune-mediated given the relapsing nature of the condition, steroid responsiveness, and absence of other identifiable causes to date, in addition to objective findings of inflammation, including the enhancing MRI lesions, and pleocytosis on CSF testing.

The patient was treated with 5 days of high-dose IV methylprednisolone (1,000 mg), with drastic improvement in gait, strength, and fatigue. He was subsequently discharged on a course of oral prednisone at 80 mg daily and slowly tapered down over several weeks. Two weeks later, his neurologic examination demonstrated near resolution of his neurologic deficits, and repeat MRI of the brain and complete spinal cord also demonstrated resolution of the enhancement.

Another case involves 31-year-old female presented with gradual progression of right-sided weakness and numbness during a three-week period that started one week after the single-dose SARS-CoV-2 vaccine Ad26.COV2.S. Neuroimaging revealed five large juxtacortical T2 FLAIR hyperintense lesions with incomplete contrast enhancement on post-contrast T1 images located supratentorial: one in the right cerebral hemisphere and four in left cerebral hemisphere. The patient was followed up for four months. Symptom debut, clinical picture and MRI were typical for ADEM and the patient completely recovered after high dose intravenous methylprednisolone treatment.

Acute disseminated encephalomyelitis is a rapidly progressive autoimmune process that is characterized by demyelination in the brain and spinal cord as a result of inflammation that occurs in response to a preceding infection or immunization. ADEM ypically presents with encephalopathy and multifocal neurological symptoms. Transverse myelitis is a similar condition that involves inflammation of the spinal cord, leading to weakness, sensory deficits, and bowel/bladder dysfunction. Optic neuritis is an inflammation of the optic nerve that can cause vision loss and pain with eye movement. 

About 200 cases of ADEM, either transverse myelitis or optic neuritis following various COVID-19 vaccines, including the vaccines from AstraZenica, Pfizer, Sputnik V, SinoVac, Moderna, Sinopharm and J&J have been described in the literature. 


REFERENCES


Roy S, Barreras P, Pardo CA, Graves JS, Zamvil SS, Newsome SD. Relapsing Encephalomyelitis After COVID-19 Infection and Vaccination: From the National MS Society Case Conference Proceedings. Neurol Neuroimmunol Neuroinflamm. 2023 Apr 4;10(3):e200112. doi: 10.1212/NXI.0000000000200112. PMID: 37015826; PMCID: PMC10074377.

Gustavsen S, Nordling MM, Weglewski A. Acute disseminated encephalomyelitis following the COVID-19 vaccine Ad26. COV2. S, a case report. Bulletin of the National Research Centre. 2023 Dec;47(1):1-5. PMID: 36643729 doi: 10.1186/s42269-023-00981-7


Comments

Post a Comment

Popular posts from this blog

A New Onset of Ulcerative Colitis post-2nd-breakthrough-COVID-19

Image
A 21-year-old non-smoking Caucasian male with a history of acute pancreatitis but no other medical issues or family history had two doses of the BNT162b2 mRNA COVID-19 vaccine.  Four months after the second dose he had his first episode of COVID-19. Although not hypoxic, he felt pretty unwell for a week, with a severe cough, fever, generalized body ache, headache, and loss of taste. He received the third dose of the vaccine two months after recovering from COVID. Nine months after the third dose, he had the second episode of COVID-19, during which he was mildly unwell for three days, recovered, and did not require any anti-viral medication or antibiotics. One week post the second episode of COVID-19, he developed diarrhea and abdominal pain. It then progressed to bloody diarrhea. Ulcerative colitis was diagnosed based on his clinical symptoms, biopsy changes, and the exclusion of other causes.  There are ten published case reports about the newly diagnosed ulcerative colitis associate
Read more

COVID in May

Image
Concerns about a potential resurgence of COVID-19 are mounting as summer 2024 approaches.  This is driven by several indicators, including social media posts, healthcare data, and wastewater surveillance across different regions. Our study findings corroborate this trend.  While many forecasters anticipate a surge, others expect a gradual increase through the end of May, and then a decline again around early June. Reports from social media suggest emerging clusters of COVID-19 in Texas, several Canadian provinces, the UK, and on cruises in northern regions such as a Norwegian cruise to Alaska.  Data from Alberta's Respiratory virus dashboard   (total weekly laboratory-confirmed COVID-19 cases) and wastewater surveillance in Calgary indicate an uptick in COVID-19 cases starting April 2024. The most recent statistics from Alberta Health reveal a significant increase in hospitalizations due to COVID-19, with 114 individuals currently hospitalized—an increase of more than 20% over two
Read more

Chronic SARS-CoV-2 Shedding

Image
Chronic viral shedding, a condition where the virus continues to be released from an individual's body long after the initial infection, has been observed in many infectious diseases, including COVID-19.  In such cases, individuals may remain asymptomatic or experience only mild symptoms while the virus persists. It remains detectable in repeated tests over an extended period and can still infect others even in nasal swab is negative (which happens quite often ). This was evident in our study.    Recent research by Conway et al. (2024) highlights the possibility of chronic SARS-CoV-2 infection, extending over several months and potentially years. Other studies have documented prolonged asymptomatic infections and extended viral shedding in moderate to severe beyond hospital discharge. Analysis of sequencing data on UK samples taken between 2 November 2020 and 15 August 2022 lead to estimates that 0.1–0.5% of infections may become persistent with typically rebounding high viral load
Read more